Cardio³ BioSciences (Braine L'Alleud, Belgium) has appointed Patrick Jeanmart as its chief financial officer. Most recently, Jeanmart was vice president of finance for IBA Molecular (Louvain-la-Neuve, Belgium), a cancer diagnostics company. Earlier in his career, he was an audit manager at Deloitte & Touche. Cardio³ BioSciences also appointed Vinciane Gaussin, PhD, as its chief scientific officer (CSO). Most recently, Gaussin was an assistant professor in the department of cell biology and molecular medicine at the University of Medicine and Dentistry of New Jersey. Cardio³ BioSciences is a biotechnology company focused on regenerating heart muscle via cardiac lineage-committed stem cell therapy for patients with congestive heart failure.
AngioDynamics Inc. (Queensbury, NY) has appointed K. Wayne McDougall to the role of vice president and corporate controller. He replaces Ron Lamy, who served as the company's corporate controller for the past five years. Prior to joining AngioDynamics, McDougall spent 10 years in the finance organization of MapInfo Corp. (Troy, NY), most recently as vice president and chief financial officer. Before MapInfo, McDougall was a business assurance manager at PricewaterhouseCoopers LLP (New York City).
St. Jude Medical Inc. (St. Paul, MN) has announced an expanded organizational structure and the appointment of several key executives to new roles, effective January 1, 2008. Dan Starks, chairman, president, and chief executive officer of St. Jude Medical, says the expanded organizational structure is part of a comprehensive program designed to double the size of St. Jude Medical within the next five years.
As part of its expanded leadership structure, the company is creating two new group president roles. Joe McCullough, currently president of St. Jude Medical's international division, and Mike Rousseau, currently president of the U.S. division, will be promoted to these newly created roles. The U.S. and international divisions will report to McCullough. The cardiac rhythm management, atrial fibrillation, cardiovascular, and neuromodulation divisions will report to Rousseau.
In conjunction with the restructuring, St. Jude Medical announced several additional senior leadership promotions. George Fazio, currently president of the cardiovascular division, will become the new president of the U.S. division. Denis Gestin, currently president of St. Jude Medical Europe, Middle East, Africa, and Canada, will become the new president of the international division. Gary Taylor, currently vice president and general manager of the company's neuromodulation business internationally, will become the new president of St. Jude Medical Europe, Middle East, Africa, and Canada. Amy Boyle, currently vice president of marketing for the international division, will be promoted to the newly created position of vice president of corporate brand and marketing. In addition, Frank Callaghan, currently vice president of research and development for the atrial fibrillation division, will become president of the cardiovascular division.
Ivivi Technologies Inc. (Northvale, NJ), a medical technology company focusing on developing an electrotherapeutic technology platform, has appointed executive vice president Edward J. Hammel to the position of chief operating officer. Hammel will continue to serve as executive vice president, a position he has held since joining the company in 2004. Prior to joining Ivivi, Hammel was a partner in Palisades Partners, a management consulting company.
NeoGuide Systems Inc. (San Jose), a developer of technology to prevent and treat colorectal cancer, has named John Cifarelli as vice president of sales. Cifarelli brings more than two decades of medical device sales experience to NeoGuide, including 18 years in management positions within the surgical products, medical systems, and endoscopy products groups of Olympus America (Center Valley, PA). He most recently served as vice president and general manager of the company's surgical products group. Prior to NeoGuide, Cifarelli was executive vice president of sales and marketing for CDx Laboratories (Suffern, NY), an emerging specialty pathology laboratory.
Biophan Technologies Inc. (Rochester, NY), a biomedical device technology developer, has disbanded its executive committee, which was formed in May 2007 to oversee the operations of the organization. Concurrently, the company named John Lanzafame as interim chief executive officer. Lanzafame began his tenure with Biophan in the position of vice president of business development in 2004, rising to his most recent position of chief operating officer in 2006. From 1989 through to 2004, Lanzafame held several senior-level executive positions at STS Biopolymers Inc., a private company that developed and manufactured high-tech, polymer-based coatings for use on medical devices.
Stentys (Paris), which is developing a next-generation drug-eluting stent for treatment of blocked coronary artery bifurcations, has appointed Hikmat Hojeibane as its chief technology officer. Previously at Johnson & Johnson Inc. (New Brunswick, NJ), Hojeibane held several technical leadership positions with increasing responsibility. His positions included director of technology assessments for Ethicon; director of research and development for Cardiovations, Johnson & Johnson's cardiac surgery division; and engineering fellow at Cordis, where he led the development of novel vascular stents and other breakthrough technologies for the treatment of vascular diseases.
In late September, the board of directors of Edwards Lifesciences (Irvine, CA) appointed Paul C. Redmond as corporate vice president for global vascular operations. Redmond joined Edwards in June 2007, bringing more than 21 years of medical device experience. Most recently, he served as vice president for cardiovascular technologies at Cordis Cardiology (Miami Lakes, FL), a Johnson & Johnson company. Previously, Redmond served as vice president for new product development at Cordis.
EyeGate Pharma (Waltham, MA), a privately held company developing iontophoresis technology to noninvasively deliver therapeutics for ocular indications, has appointed Paul G. Chaney as a member of its board of directors. Chaney is executive vice president of OSI Pharmaceuticals (Melville, NY) and president of Eyetech, OSI's eyecare subsidiary. Prior to the merger of Eyetech with OSI, Chaney served as chief operating officer of Eyetech.
The board of directors of Cooper Companies, Inc. (Lake Forest, CA) has elected Robert S. Weiss as its chief executive officer, succeeding A. Thomas Bender effective November 1. Weiss has been a member of Cooper's board of directors and has held a number of senior management roles in the company, including his most recent position as executive vice president and chief operating officer since January 2005. Weiss joined the company in 1977. He has served as executive vice president since October 1995 and chief financial officer from September 1989 to January 2005. In April 2007, he became president of CooperVision, the company's contact lens unit.
Medical device and diagnostics manufacturer Iris International Inc. (Chatsworth, CA) appointed Peter L. Donato as corporate vice president and chief financial officer. Donato replaces Veronica Tarrant, who had been serving as interim CFO and has now resumed her former duties as vice president of finance and corporate controller. Prior to his appointment at Iris, Donato was chief financial officer for Gamma Medica-Ideas (Northridge, CA), a privately held medical imaging equipment manufacturer. Before that, from 2003 to 2006, he served as a divisional chief financial officer and vice president of Accellent Cardiology (Brooklyn Park, MN).
Rodney W. Schutt has been named chief operating officer of medical technology developer Luminetx Corp. (Memphis). The company reports that Schutt's immediate focus will be to implement business development strategies, build a larger U.S. sales network, and streamline operational processes to increase Luminetx's sales and revenues. Prior to joining Luminetx, Schutt held the position of vice president of business development in Asia for Smith and Nephew (London). Schutt began his career in engineering at GE Healthcare (Chalfont St. Giles, UK). During his 18-year career at GE Healthcare, he held various leadership positions ending as general manager of GE Healthcare's consulting business.
TheraGenetics Ltd. (London), a personalized diagnostics company focused on central nervous system (CNS) disorders, has appointed Heiner Dreismann, PhD, as chairman of its board and Robert Forrester as a director. Dreismann most recently served as president and chief executive officer of Roche Molecular Systems Inc. (Pleasanton, CA). Forrester serves as executive vice president and chief financial officer of CombinatoRx Inc. (Cambridge, MA).